• +1-646-491-9876
    • +91-20-67278686

    Search

    Pulmonary Arterial Hypertension - Pipeline Review, H1 2017

    Pulmonary Arterial Hypertension - Pipeline Review, H1 2017

    • Report Code ID: RW0001689465
    • Category Healthcare
    • No. of Pages 227
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

    Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 9, 11, 36, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 7
    Introduction 8
    Publisher Report Coverage 8
    Pulmonary Arterial Hypertension - Overview 9
    Pulmonary Arterial Hypertension - Therapeutics Development 10
    Pipeline Overview 10
    Pipeline by Companies 11
    Pipeline by Universities/Institutes 15
    Products under Development by Companies 16
    Products under Development by Universities/Institutes 20
    Pulmonary Arterial Hypertension - Therapeutics Assessment 21
    Assessment by Target 21
    Assessment by Mechanism of Action 24
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 31
    Actelion Ltd 31
    APT Therapeutics Inc 31
    Arena Pharmaceuticals Inc 32
    Ascendis Pharma A/S 32
    Asklepion Pharmaceuticals LLC 33
    AVEO Pharmaceuticals Inc 33
    Bial - Portela & Ca SA 34
    Camurus AB 34
    Celsion Corp 35
    Celtaxsys Inc 35
    Chiesi Farmaceutici SpA 36
    Eli Lilly and Company 36
    F. Hoffmann-La Roche Ltd 37
    Galectin Therapeutics Inc 37
    HitGen LTD 38
    Insmed Inc 38
    INSYS Therapeutics Inc 39
    INVENT Pharmaceuticals Inc 39
    Johnson & Johnson 40
    Kowa Company Ltd 40
    Liquidia Technologies Inc 41
    MannKind Corp 41
    Mast Therapeutics Inc 42
    Mezzion Pharma Co Ltd 42
    miRagen Therapeutics Inc 43
    Morphogen-IX Ltd 43
    Nippon Kayaku Co Ltd 44
    Nippon Shinyaku Co Ltd 44
    Northern Therapeutics Inc 45
    Novartis AG 45
    Peloton Therapeutics Inc 46
    PhaseBio Pharmaceuticals Inc 46
    Pluristem Therapeutics Inc 47
    Polyphor Ltd 47
    Proteo Inc 48
    Pulmokine Inc 48
    Reata Pharmaceuticals Inc 49
    Respira Therapeutics Inc 49
    Reviva Pharmaceuticals Inc 50
    Selten Pharma Inc 50
    Serodus ASA 51
    Silence Therapeutics Plc 51
    SteadyMed Therapeutics Inc 52
    Suda Ltd 52
    Toray Industries Inc 53
    United Therapeutics Corp 53
    Vivus Inc 54
    Pulmonary Arterial Hypertension - Drug Profiles 55
    (macitentan + tadalafil) - Drug Profile 55
    acebilustat - Drug Profile 56
    Antibody to Inhibit TRAIL for Pulmonary Arterial Hypertension - Drug Profile 60
    Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 61
    APT-602 - Drug Profile 62
    ascomycin - Drug Profile 63
    AV-353 - Drug Profile 64
    bardoxolone methyl - Drug Profile 65
    beraprost sodium SR - Drug Profile 71
    BIA-51058 - Drug Profile 72
    BMP-10 - Drug Profile 73
    BMP-9 - Drug Profile 74
    Cell Therapy to Activate eNOS for Pulmonary Arterial Hypertension - Drug Profile 75
    CTX-3397 - Drug Profile 76
    Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 77
    esuberaprost sodium MR + treprostinil - Drug Profile 78
    GMA-301 - Drug Profile 79
    GMCT-01 - Drug Profile 80
    GRMD-02 - Drug Profile 84
    INS-1009 - Drug Profile 97
    INV-240 - Drug Profile 99
    JNJ-26993135 - Drug Profile 100
    KAR-5585 - Drug Profile 101
    L-Citrulline - Drug Profile 102
    macitentan - Drug Profile 104
    MD-0701 - Drug Profile 110
    MFC-1040 - Drug Profile 112
    MFC-2040 - Drug Profile 113
    NK-104 NP - Drug Profile 114
    Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile 115
    Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 116
    PB-1046 - Drug Profile 117
    PB-1120 - Drug Profile 120
    PF-543 - Drug Profile 121
    PK-10453 - Drug Profile 122
    PK-10571 - Drug Profile 123
    PLX-PAD - Drug Profile 124
    POL-6014 - Drug Profile 135
    PT-2977 - Drug Profile 137
    QCC-374 - Drug Profile 138
    R-190 - Drug Profile 139
    ralinepag - Drug Profile 141
    RP-5063 - Drug Profile 143
    RT-234 - Drug Profile 145
    selexipag - Drug Profile 146
    SER-100 - Drug Profile 151
    sildenafil citrate - Drug Profile 154
    sirolimus - Drug Profile 155
    sirolimus albumin-bound - Drug Profile 156
    Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile 158
    Small Molecules for Pulmonary Arterial Hypertension - Drug Profile 159
    Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 160
    Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 161
    Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile 162
    Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 163
    sodium nitrite - Drug Profile 164
    SPI-054 - Drug Profile 168
    SPI-183 - Drug Profile 169
    SUD-004 - Drug Profile 170
    Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 171
    tacrolimus - Drug Profile 172
    tadalafil - Drug Profile 173
    tiprelestat - Drug Profile 175
    tocilizumab - Drug Profile 179
    TPN-729 - Drug Profile 189
    TR-422 - Drug Profile 190
    treprostinil diolamine - Drug Profile 191
    treprostinil diolamine - Drug Profile 193
    treprostinil diolamine - Drug Profile 195
    treprostinil diolamine - Drug Profile 196
    treprostinil diolamine SR - Drug Profile 197
    ubenimex - Drug Profile 198
    udenafil - Drug Profile 200
    VPD-380 - Drug Profile 204
    Pulmonary Arterial Hypertension - Dormant Projects 205
    Pulmonary Arterial Hypertension - Discontinued Products 207
    Pulmonary Arterial Hypertension - Product Development Milestones 208
    Featured News & Press Releases 208
    Appendix 220
    Methodology 220
    Coverage 220
    Secondary Research 220
    Primary Research 220
    Expert Panel Validation 220
    Contact Us 220
    Disclaimer 221

    List of Tables

    Number of Products under Development for Pulmonary Arterial Hypertension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by INSYS Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Kowa Company Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Polyphor Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Proteo Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Selten Pharma Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H1 2017
    Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H1 2017
    Pulmonary Arterial Hypertension - Dormant Projects, H1 2017
    Pulmonary Arterial Hypertension - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Pulmonary Arterial Hypertension - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Pulmonary Arterial Hypertension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Actelion Ltd
    APT Therapeutics Inc
    Arena Pharmaceuticals Inc
    Ascendis Pharma A/S
    Asklepion Pharmaceuticals LLC
    AVEO Pharmaceuticals Inc
    Bial - Portela & Ca SA
    Camurus AB
    Celsion Corp
    Celtaxsys Inc
    Chiesi Farmaceutici SpA
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Galectin Therapeutics Inc
    HitGen LTD
    Insmed Inc
    INSYS Therapeutics Inc
    INVENT Pharmaceuticals Inc
    Johnson & Johnson
    Kowa Company Ltd
    Liquidia Technologies Inc
    MannKind Corp
    Mast Therapeutics Inc
    Mezzion Pharma Co Ltd
    miRagen Therapeutics Inc
    Morphogen-IX Ltd
    Nippon Kayaku Co Ltd
    Nippon Shinyaku Co Ltd
    Northern Therapeutics Inc
    Novartis AG
    Peloton Therapeutics Inc
    PhaseBio Pharmaceuticals Inc
    Pluristem Therapeutics Inc
    Polyphor Ltd
    Proteo Inc
    Pulmokine Inc
    Reata Pharmaceuticals Inc
    Respira Therapeutics Inc
    Reviva Pharmaceuticals Inc
    Selten Pharma Inc
    Serodus ASA
    Silence Therapeutics Plc
    SteadyMed Therapeutics Inc
    Suda Ltd
    Toray Industries Inc
    United Therapeutics Corp
    Vivus Inc

    Request for Sample

    Report Url http://www.reportsweb.com//pulmonary-arterial-hypertension-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//pulmonary-arterial-hypertension-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//pulmonary-arterial-hypertension-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments